Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions

SAN DIEGO, June 20, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced three upcoming data presentations for it Ultrafast Insulin programs at the American Diabetes Association (ADA) 71st Scientific Sessions taking place June 24-28, 2011 at the San Diego Convention Center.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentations include a late-breaking abstract on the safety and efficacy of Aspart-PH20, a formulation of Halozyme's rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog^®, administered via continuous pump infusion in type 1 diabetes patients over three days. A second presentation tests the safety and evaluates whether regular insulin can be made as fast as an analog. The presentations are scheduled as follows:

Oral Presentation
Saturday – June 25, 2011
1:45 – 2:00 p.m.: Comparison of Human Hyaluronidase + Recombinant Human Insulin (RHI) vs. Insulin Lispro in a Basal-Bolus Regimen in Patients with Type 1 Diabetes (T1DM)
Abstract Number: 0069-OR
Presented during session: Pharmacologic Treatment of Diabetes-Insulin Therapy

Late Breaker Poster – Insulin Pump Study
Sunday – June 26, 2011
12:00 – 2:00 p.m.: Addition of Human Hyaluronidase to Rapid Analog Insulin Reduces the Absolute Variability of Early Insulin Absorption across Infusion Set Life
Abstract Number: 0027-LB
Location: Hall B – Poster Hall

Poster
Sunday – June 26, 2011
1:00 – 2:00 p.m.: Human Hyaluronidase Coinjection Consistently Accelerates Prandial Insulin Pharmacokinetics (PK) and Glucodynamics (GD) across Studies and Populations
Abstract Number: 0965-P
Location: Hall B – Poster Hall

Abstracts for these presentations may be found by visiting the ADA Scientific Sessions Web site.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze^™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Baxter, Roche, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including immunoglobulin, Herceptin^®, MabThera^®, Cinryze^® and alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Halozyme Contact
Robert H. Uhl
Senior Director, Investor Relations
(858) 704-8264
[email protected]

Media Contact
Ligia Santos
415-946-1083
[email protected]

SOURCE Halozyme Therapeutics, Inc.